---
title: "Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286966420.md"
description: "Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO, agreeing to pay $4.25 million in fixed fees and up to $4 million in sales milestones. Eton will share 55% of annual net sales up to $7 million and 50% above that. The agreement, effective from September 26, 2026, includes a term until March 31, 2032, with potential renewals. Symphony Health projects 2025 U.S. sales of $8.1 million."
datetime: "2026-05-19T20:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286966420.md)
  - [en](https://longbridge.com/en/news/286966420.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286966420.md)
generator: "portal-rs"
---

# Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share

Eton Pharmaceuticals entered into an exclusive U.S. supply and distribution agreement for the commercialization rights to IMPAVIDO (miltefosine). Eton will pay $4.25 million in fixed fees through March 31, 2032, plus up to $4.0 million in sales milestones, and will remit 55% of annual net sales up to $7.0 million and 50% above that. The Supplier will cover product and regulatory costs while Eton funds sales and marketing; exclusivity begins September 26, 2026. Symphony Health reported 2025 U.S. sales of $8.1 million.

**Agreement details:**

-   **Agreement type**: Exclusive U.S. commercialization supply and distribution agreement for IMPAVIDO
-   **Counterparty**: Knight Therapeutics (affiliate)
-   **Signed / Effective**: May 18 2026 / Sep 26 2026
-   **Duration / Termination**: Initial term to Mar 31 2032; up to ten 1-year renewals
-   **Reason**: Expand orphan drug portfolio with exclusive U.S. rights to IMPAVIDO

Original SEC Filing: Eton Pharmaceuticals, Inc. \[ ETON \] - 8-K - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Eton Pharma Chief Business Officer David Krempa reports disposal of 25,000 common shares valued at $1.63 million](https://longbridge.com/en/news/296830319.md)
- [Eton Pharma President and CEO Sean Brynjelsen sells USD 6.19 million in common shares](https://longbridge.com/en/news/296542074.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [ETON: Record Q2 revenue and raised 2026 guidance reflect strong rare disease portfolio momentum](https://longbridge.com/en/news/295841094.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**